Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
Anebulo Pharmaceuticals Inc
Accrued Liabilities
Anebulo Pharmaceuticals Inc
Accrued Liabilities Peer Comparison
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
Accrued Liabilities
$530k
|
CAGR 3-Years
198%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Accrued Liabilities
$28.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accrued Liabilities
$9.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
Pfizer Inc
NYSE:PFE
|
Accrued Liabilities
$2.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Merck & Co Inc
NYSE:MRK
|
Accrued Liabilities
$13.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
Eli Lilly and Co
NYSE:LLY
|
Accrued Liabilities
$10.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
See Also
What is Anebulo Pharmaceuticals Inc's Accrued Liabilities?
Accrued Liabilities
530k
USD
Based on the financial report for Jun 30, 2023, Anebulo Pharmaceuticals Inc's Accrued Liabilities amounts to 530k USD.
What is Anebulo Pharmaceuticals Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
198%
Over the last year, the Accrued Liabilities growth was 308%. The average annual Accrued Liabilities growth rates for Anebulo Pharmaceuticals Inc have been 198% over the past three years .